Fibrin Degradation Products During Postoperative Radiotherapy of Ovarian Carcinoma

Svanberg, L; Åstedt, Birger; Gynning, Inge; Nilsson, Inga Marie

doi:10.3109/00016347309158302

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…antithrombin III) with reactive fibrinolysis (D-dimer). This phenomenon has also been reported in a number of other cancer types (14)(15)(16). The elevated thrombinantithrombin HI levels are consistent with an earlier study on this topic, in which thrombin-antithrombin III was considered a marker of malignant gynaecological disease (17).…”

Section: Discussionsupporting

confidence: 78%

Haemostasis Activation Markers in Plasma of Patients with Benign and Malignant Gynaecological Tumours: A Pilot Study

Wersch

Peters²,

Ubachs³

1995

CCLM

View full text Add to dashboard Cite

Summary: Coagulation and fibrinolysis activation have been investigated in fifty-eight women with recently detected gynaecological tumours. Twenty-six were benign and 32 malignant: of the last group nine patients had metastases. A control group consisted of 31 age-matched healthy women. Prothrombin fragment 1 + 2, thrombinantithrombin III and D-dimer were measured. The median values of all analytes were significantly higher in the malignant tumour group, but not in the benign tumour group, as compared to the control group. The group of patients with a gynaecological tumour and metastases differed from the non-metastasized tumour group in prothrombin fragment 1-1-2, thrombin-antithrombin III and D-dimer. In the non-metastasized malignant tumour group solely prothrombin fragment 1 + 2 was significantly higher than in the benign tumour group. Coagulation and fibrinolysis appeared to be activated in the patients with a metastasized gynaecological tumour, fibrinolysis predominating as can be derived from the elevated D-dimer/thrombin-antithrombin III and D-dimer/prothrombin fragment 1 + 2 ratios. The studied constituents do not enable a differentiation between the benign and malignant processes. However, as the differences of these values in both malignant tumour groups were significant, this might be used to trace the existence of metastases in gynaecological tumours. Investigation of these analytes in several specific types of gynaecological tumours might be clinically relevant.

show abstract

Section: Discussionsupporting

confidence: 78%

Haemostasis Activation Markers in Plasma of Patients with Benign and Malignant Gynaecological Tumours: A Pilot Study

Wersch

Peters²,

Ubachs³

1995

CCLM

View full text Add to dashboard Cite

show abstract

“…Evidence of DIC and particularly of fibrinolysis (elevated FSP) may be used to judge the efficacy of treatment and whether there is a recurrence [171,221]. There are reports of successful control of bleeding with heparin in some patients with cancer and DIC [119] such as neuroblastoma [68] or cancer of the biliary tract [131].…”

Section: Neoplasmsmentioning

confidence: 99%

Chronic Intravascular Coagulation and Fibrinolysis (ICF) Syndromes (DIC)

Owen¹,

Bowie²

2008

Semin Thromb Hemost

View full text Add to dashboard Cite

Local haemostasis in brain tumours

1975

View full text Add to dashboard Cite

The thromboplastic activity and the fibrinolytic activity were examined in 7 human meningiomas and 6 gliomas obtained at neurosurgery. Two different haemostatic patterns emerged, meningiomas having lower thromboplastic and higher fibrinolytic activity than that of gliomas. This difference might help to explain the better haemostatic capacity of gliomas during and after operation than that of meningiomas.

show abstract

Fibrin Degradation Products During Postoperative Radiotherapy of Ovarian Carcinoma

Cited by 4 publications

References 11 publications

Haemostasis Activation Markers in Plasma of Patients with Benign and Malignant Gynaecological Tumours: A Pilot Study

Haemostasis Activation Markers in Plasma of Patients with Benign and Malignant Gynaecological Tumours: A Pilot Study

Chronic Intravascular Coagulation and Fibrinolysis (ICF) Syndromes (DIC)

Local haemostasis in brain tumours

Contact Info

Product

Resources

About